Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone

A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation

(2015) Jeff Patrick et al.   POSTGRADUATE MEDICINE

A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder

(2015) Yuan Hwa Chou et al.   Clinical Psychopharmacology and Neuroscience

Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain

(2015) Martin Hale et al.   Journal of Pain Research

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease

(2014) R. A. Hauser et al.   EUROPEAN JOURNAL OF NEUROLOGY

A Randomized Placebo-Controlled Double-Blind Study Evaluating the Time Course of Response to Methylphenidate Hydrochloride Extended-Release Capsules in Children with Attention-Deficit/Hyperactivity Disorder

(2014) Sharon B. Wigal et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Does short-term placebo response predict the long-term observation? Meta-analysis on forced expiratory volume in 1 second from asthma trials

(2014) Shuying Yang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

(2014) Adriaan Cleton et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials

(2013) Navin Goyal et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

(2013) Angelo Sambunaris et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Pharmacokinetic–pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score

(2013) Venkatesh Pilla Reddy et al.   SCHIZOPHRENIA RESEARCH

Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility

(2013) Venkatesh Pilla Reddy et al.   SCHIZOPHRENIA RESEARCH

A Novel Metric to Assess the Clinical Utility of a Drug in the Presence of Efficacy and Dropout Information

(2011) N Goyal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy

(2010) Pei-min Yu et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

(2009) Mahesh N. Samtani et al.   CLINICAL PHARMACOKINETICS

Change in formulation and its potential clinical and pharmacoeconomic value: example of extended release venlafaxine

(2009) Jean-Marc C. Haeusler   CURRENT MEDICAL RESEARCH AND OPINION

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity

(2009) Gianluca Nucci et al.   Expert Opinion on Drug Discovery

The FDA Critical Path Initiative and Its Influence on New Drug Development

(2008) Janet Woodcock et al.   Annual Review of Medicine

Quantitative Disease, Drug, and Trial Models

(2008) Jogarao V.S. Gobburu et al.   Annual Review of Pharmacology and Toxicology

Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride

(2008) Lawrence S Kegeles et al.   NEUROPSYCHOPHARMACOLOGY